New drug proves to be promising for pancreatic cancer
Researchers have invented a new drug for treating pancreatic cancer, which also showed promising initial results.
Radiation and chemotherapy drug gemcitabine, which are the standard treatment for pancreatic cancer, both work by causing damage to DNA. But pancreatic cancer has a way of repairing that damage, which limits how effective these therapies can be.
Researchers found that AZD1775 prevented pancreatic cancer from protecting itself against the effects of radiation and gemcitabine, while leaving normal cells relatively unaffected.
If we can disable the DNA damage response in pancreatic cancer cells, it might eliminate treatment resistance and sensitize cancer to the effects of both radiation and chemotherapy, said an associate Prof. of radiation oncology.
According to the study, the trial enrolled 34 patients with locally advanced pancreatic cancer.
Patients received AZD1775 in addition to radiation and gemcitabine. The goal of the study was to determine the maximum tolerated dose of AZD2775 in this combination. In the process, the researchers also found that this combination resulted in better than expected overall survival.
Pancreatic cancer is particularly known for spreading to distant parts of the body, part of the reason overall 5-year survival is just 9%.
If we're ever going to cure pancreatic cancer, we're going to need effective systemic treatment as well as local therapy. Our data suggest that AZD1775 can do both, said the senior author of the study.
The median overall survival in the study was 22 months, with no progression for a median of 9 months. A previous study using gemcitabine alone in a similar group of patients found an overall survival of 12-14 months.
Adding AZD1775 to radiation and gemcitabine was relatively well tolerated with encouraging survival results. Further studies with promising combination are needed, the author concluded.
Radiation and chemotherapy drug gemcitabine, which are the standard treatment for pancreatic cancer, both work by causing damage to DNA. But pancreatic cancer has a way of repairing that damage, which limits how effective these therapies can be.
Researchers found that AZD1775 prevented pancreatic cancer from protecting itself against the effects of radiation and gemcitabine, while leaving normal cells relatively unaffected.
If we can disable the DNA damage response in pancreatic cancer cells, it might eliminate treatment resistance and sensitize cancer to the effects of both radiation and chemotherapy, said an associate Prof. of radiation oncology.
According to the study, the trial enrolled 34 patients with locally advanced pancreatic cancer.
Patients received AZD1775 in addition to radiation and gemcitabine. The goal of the study was to determine the maximum tolerated dose of AZD2775 in this combination. In the process, the researchers also found that this combination resulted in better than expected overall survival.
Pancreatic cancer is particularly known for spreading to distant parts of the body, part of the reason overall 5-year survival is just 9%.
If we're ever going to cure pancreatic cancer, we're going to need effective systemic treatment as well as local therapy. Our data suggest that AZD1775 can do both, said the senior author of the study.
The median overall survival in the study was 22 months, with no progression for a median of 9 months. A previous study using gemcitabine alone in a similar group of patients found an overall survival of 12-14 months.
THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE
HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES.
PS-
THOSE INTERESTED IN
RECIPES ARE FREE TO VIEW MY BLOG-
https://gseasyrecipes.blogspot.com/
FOR INFO ABOUT KNEE
REPLACEMENT, YOU CAN VIEW MY BLOG-
https:// kneereplacement-stickclub.blogspot.com/
FOR
CROCHET DESIGNS
https://gscrochetdesigns.blogspot.com
Adding AZD1775 to radiation and gemcitabine was relatively well tolerated with encouraging survival results. Further studies with promising combination are needed, the author concluded.
Labels: AZD1775, effects, gemcitabine, new drug, normal cells, Pancreatic Cancer, prevented, promising results, Protect, RADIATION, unaffected
0 Comments:
Post a Comment
<< Home